메뉴 건너뛰기




Volumn 22, Issue 19, 2014, Pages 5290-5297

Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors

Author keywords

Antiviral activity; Drug design; HIV; Molecular modeling; NNRTIs; Pyrimidine; SAR; SCR

Indexed keywords

1 N (2 BROMO 4 SULFONAMIDEPHENYL) 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOATE; 2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO] N (2 NITROPHENYL)ACETAMIDE; 3 CHLORO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOIC ACID; 3 CHLORO N HYDROXY 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZAMIDE; 3 CHLORO N METHOXY 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZAMIDE; 4 [4 [[5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]METHYL] 1H 1,2,3 TRIAZOL 1 YL]BENZOIC ACID; 4 [[1 (2 BROMOBENZYL) 1H 1,2,3 TRIAZOL 4 YL]METHYLTHIO] 5 (NAPHTHALEN 1 YL)PYRIMIDINE; 4 [[1 (4 METHOXYBENZYL) 1H 1,2,3 TRIAZOL 4 YL]METHYLTHIO] 5 (NAPHTHALEN 1 YL)PYRIMIDINE; 6 CHLORO 5 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]PICOLINIC ACID; ACETANILIDE DERIVATIVE; ARYLAZINYLTHIOACETANILIDE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; ETHYL 2 [3 CHLORO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZAMIDO]ACETATE; ETHYL 2 [3 CHLORO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZAMIDO]PROPANOATE; ETHYL 3 BROMO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOATE; ETHYL 3 CHLORO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOATE; METHYL 3 BROMO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOATE; METHYL 3 CHLORO 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO]BENZOATE; METHYL 4 [2 [5 (NAPHTHALEN 1 YL)PYRIMIDIN 4 YLTHIO]ACETAMIDO] 3 NITROBENZOATE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMIDINYLTHIOACETANILIDE DERIVATIVE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINE DERIVATIVE;

EID: 84907543301     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2014.08.001     Document Type: Article
Times cited : (13)

References (30)
  • 13
    • 84903743047 scopus 로고    scopus 로고
    • Parts 1-10 were reviewed in 12(a,b)
    • Parts 1-10 were reviewed in 12(a,b): Y. Song, P. Zhan, and X. Liu Curr. Pharm. Des. 19 2013 7141
    • (2013) Curr. Pharm. Des. , vol.19 , pp. 7141
    • Song, Y.1    Zhan, P.2    Liu, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.